Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving outcomes in transplantation.

Wolfram Brugger1

  • 1Eberhard-Karls Universität, Hämatologie und Onkologie, Medizinische Klinik II, Tübingen, Germany.

Seminars in Oncology
|June 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Cancer research communications·2026
Same author

CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease.

The New England journal of medicine·2026
Same author

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Haematologica·2026
Same author

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

The New England journal of medicine·2024
Same author

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

Nature medicine·2024
Same author

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.

European journal of haematology·2024
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Rituximab as post-transplant therapy significantly improves outcomes for follicular lymphoma and mantle cell lymphoma. This treatment leads to high complete remission rates and eliminates minimal residual disease, offering a potentially curative option.

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Follicular lymphoma and mantle cell lymphoma are aggressive B-cell malignancies with poor prognoses using standard chemotherapy.
  • High-dose therapy with autologous stem cell transplantation (ASCT) is a treatment intensification strategy for these incurable lymphomas.
  • Rituximab, an anti-CD20 monoclonal antibody, targets B-cell surface antigens and can be used in ASCT for lymphoma management.

Purpose of the Study:

  • To evaluate the safety and efficacy of rituximab as a post-transplant consolidation therapy in patients with follicular lymphoma and mantle cell lymphoma undergoing ASCT.
  • To assess the impact of rituximab on remission rates and minimal residual disease (MRD) after ASCT.

Main Methods:

  • A multicenter study involving patients with follicular lymphoma and mantle cell lymphoma who received high-dose therapy and ASCT.

Related Experiment Videos

  • Rituximab was administered as a post-transplant consolidation therapy.
  • Patients were monitored for remission status and molecular markers of MRD (bcl-1 and bcl-2 chromosomal rearrangements) via polymerase chain reaction (PCR).

    • Main Results:

    • At 18-month follow-up, 92% of patients achieved complete remission.
    • All evaluable patients became PCR-negative for bcl-1 and bcl-2 chromosomal rearrangements six months after treatment.
    • Sustained PCR negativity was observed during follow-up, indicating elimination of MRD.

    Conclusions:

    • Rituximab as post-transplant consolidation therapy is a valuable treatment for follicular lymphoma and mantle cell lymphoma.
    • This approach leads to high rates of durable complete remissions.
    • Rituximab effectively eliminates minimal residual disease, suggesting a potentially curative role in these B-cell malignancies.